Actively Recruiting
CAPA In-vitro Oocyte Maturation
Led by Chinese University of Hong Kong · Updated on 2025-12-08
100
Participants Needed
1
Research Sites
342 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.
CONDITIONS
Official Title
CAPA In-vitro Oocyte Maturation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged from 0-50 years old
- Patients seek fertility preservation services
- Patients seek oocyte retrieval services
You will not qualify if you...
- Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Prince of Wales Hospital
Hong Kong, Hong Kong
Actively Recruiting
Research Team
P
Pui Wah Jacqueline Chung
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here